About elranatamab bcmm
BCMA-directed bispecific antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after at least four prior therapies.
Usual adult dose
Subcutaneous injection: 12 mg on day 1, 32 mg on day 4, then 76 mg weekly through week 24; afterward every two weeks if responding.
Common side effects
- Infections
- Low blood cell counts
- Cytokine release syndrome
- Neurologic problems, including confusion
Important warnings
- Can cause life-threatening cytokine release syndrome and neurologic toxicity.
- Infections can be severe or fatal; blood counts require monitoring.
- Treatment begins with step-up doses and monitoring after initial injections.
- May harm an unborn baby; effective contraception is required during treatment and for four months afterward.
Pregnancy
May cause fetal harm. Human pregnancy data are insufficient; effective contraception is recommended during treatment and for four months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for four months after the last dose.
Interactions
- May affect the effectiveness of some medicines metabolized by CYP enzymes; review medicines with the care team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.